pdufa.bio
Home › Decisions › CORT 2026-03-25

CORT FDA decision — Mar 25, 2026

✓ APPROVED

Corcept Therapeutics Incorporated — Lifyorli (relacorilant) plus ABRAXANE (nab-p · Ovarian cancer.

Run-up into the decision (T-120 → T+5)

PDUFA 3/25/26$90.32$32.1510/8/25
Daily close, T-120 (10/8/25) through T+5. Run-up high $90.32 on 10/14/25, low $32.15 on 3/13/26 (T-120 to T-1). FDA decision 3/25/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-03-25
OutcomeApproved
Drug / candidateLifyorli (relacorilant) plus ABRAXANE (nab-p
CompanyCorcept Therapeutics Incorporated
120-day run-up (T-120→T-1)-59.9%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio